

Cover Story
Guest Editorial
As the world faced the threat of a novel respiratory pathogen, SARS-CoV-2, in the first months of 2020, there was a great deal of uncertainty about its effect on people, especially those living with a diagnosis of cancer.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Protecting the cure: Why the future of radiation oncology must be precision-guided
- Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research - NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Wafik El-Deiry steps down as director of Brown’s Legorreta Cancer Center














